share_log

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.7%)

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.7%)

Arcutis Biotherapeutics | SC 13G/A：超过5%持股股东披露文件(修正)-BlackRock, Inc.(7.7%)
美股SEC公告 ·  10/23 03:31

Moomoo AI 已提取核心信息

BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on October 22, 2024, indicating a 7.7% ownership stake in Arcutis Biotherapeutics, a biopharmaceutical company. The filing, which is a standard disclosure for entities owning more than 5% of a company's stock, shows that BlackRock has sole dispositive power over 9,029,624 shares of Arcutis Biotherapeutics' common stock. The document clarifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The address of BlackRock's principal business office is listed as 50 Hudson Yards, New York, NY 10001. The filing includes a list of subsidiaries under BlackRock, Inc. and a power of attorney granting authority to certain individuals to execute documents necessary for compliance with regulatory requirements.
BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on October 22, 2024, indicating a 7.7% ownership stake in Arcutis Biotherapeutics, a biopharmaceutical company. The filing, which is a standard disclosure for entities owning more than 5% of a company's stock, shows that BlackRock has sole dispositive power over 9,029,624 shares of Arcutis Biotherapeutics' common stock. The document clarifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The address of BlackRock's principal business office is listed as 50 Hudson Yards, New York, NY 10001. The filing includes a list of subsidiaries under BlackRock, Inc. and a power of attorney granting authority to certain individuals to execute documents necessary for compliance with regulatory requirements.
贝莱德，一家总部位于特拉华州的大型投资管理公司，于2024年10月22日向证券交易委员会提交了修订后的13G表格，显示其持有Arcutis Biotherapeutics 7.7%的股权。该申报文件是针对持有公司5%以上股份的实体的标准披露，显示贝莱德对Arcutis Biotherapeutics普通股拥有9,029,624股的唯一处置权。文件澄清了这些股份是在日常业务过程中获得的，而不是为了改变或影响发行人的控制权。贝莱德的主营办公地址列在纽约市哈德逊城50号邮编10001。申报文件包括贝莱德公司下的子公司名单以及授权特定个人执行必要文件以遵守监管要求的授权委托书。
贝莱德，一家总部位于特拉华州的大型投资管理公司，于2024年10月22日向证券交易委员会提交了修订后的13G表格，显示其持有Arcutis Biotherapeutics 7.7%的股权。该申报文件是针对持有公司5%以上股份的实体的标准披露，显示贝莱德对Arcutis Biotherapeutics普通股拥有9,029,624股的唯一处置权。文件澄清了这些股份是在日常业务过程中获得的，而不是为了改变或影响发行人的控制权。贝莱德的主营办公地址列在纽约市哈德逊城50号邮编10001。申报文件包括贝莱德公司下的子公司名单以及授权特定个人执行必要文件以遵守监管要求的授权委托书。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间